Patrick Daly

DocwireNews

Investigators sought to characterize first-line and subsequent therapies for immune thrombocytopenia (ITP) used in Australia, noting that access to recommended second-line therapies, including rituximab and thrombopoietin agonists (TPO-A) is restricted in the country. The authors identified a wide range of second-line agents with differing efficacy and safety profiles, with rituximab and TPO-A demonstrating the strongest efficacy.
The analysis, published in Research and Practice in Thrombosis and Haemostasis, included 322 retrospective patients with ITP treated at 8 participating centers across Australia between 2013 and 2020. Mean age at diagnosis was 48.8 ± 22.6 years, and 58.3% of patients were women. Researchers compared data and frequency among centers using descriptive statistics, pivot tables, and paired t tests.
<h2>Effective Second-Line Options Exist, but Australians Lack Access</h2>
The ITP diagnosis was primary in 72% of patients and secondary in 28%, and 95% of patients had first-line treatment with 1 or more of prednisolone (76%), dexamethasone (15%), or intravenous immunoglobulin (48%). Notably, patients with secondary ITP were less steroid-dependent (72% vs 76%) and required less second-line therapy (47% vs 58%).
More than half (56%) the cohort received 1 or more second-line agents, and the mean number of second-line therapies per patient was 1.9 ± 1.2. The most commonly used treatments were rituximab, eltrombopag, and splenectomy, which yielded the highest rates of complete response at 60.3%, 72.1%, and 71.8%, respectively. The authors noted that long-term corticosteroids and splenectomy had the least favorable side effects.
Ultimately, the study’s authors judged that effective second-line therapies for ITP are available, but they reemphasized that access to these agents is limited in Australia and there is a lack of direct comparison studies. Consequently, treatment choices are largely based on the experience of individual providers.
Related: <a href="https://www.docwirenews.com/docwire-pick/value-of-peripheral-blood-lymphocytes-in-detecting-immune-thrombocytopenia/">Value of Peripheral Blood Lymphocytes in Detecting Immune Thrombocytopenia</a>

Andrew Moreno

Genetic Classification Model Differentiates MDS Stem, Progenitor Cells from Healthy Bone Marrow

ASH 2024

Cecilia Brown

FDA Grants Breakthrough Therapy Designation to Sacituzumab Govitecan for Second-Line Treatment of ES-SCLC

Small Cell Lung Cancer

Genetic Study Uncovers Potential Therapy-Actionable Transcription Factors in MDS

Latest News

First-Line and Subsequent ITP Therapies Under Australia’s Treatment Restrictions

Investigators sought to characterize first-line and subsequent therapies for immune thrombocytopenia (ITP) used in Australia, noting that access to recommended second-line ...

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe